Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Organetix is a biotechnology company specializing in the development of advanced organ-on-a-chip technology and microphysiological systems (MPS). Spun out from the University of Pennsylvania and founded by Dr. Dan Huh, the company creates microfluidic platforms that replicate the complex physiological environments and functions of human organs, such as the lung, eye, and placenta. These bioengineered models are designed to provide high-fidelity, human-relevant data for drug discovery, safety assessment, and disease modeling, offering a more predictive alternative to traditional animal testing. Organetix aims to accelerate the development of new therapeutics by providing researchers with sophisticated tools to study tissue-level responses and barrier functions in a controlled, in vitro setting. The company's technology is particularly focused on modeling barrier tissues and complex physiological interactions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Organetix.